Medical Group will be first in U.S. to offer
BreastSentry® diagnostic test
TORONTO, March 16, 2017 /PRNewswire/ - GeneNews Limited
(TSX:GEN) ("GeneNews" or the "Company") announced today that it has
signed an agreement with a large, multi-specialty physician group
in the American Midwest for use of its cancer diagnostic tests. The
contract represents the second partnership agreement with a U.S.
healthcare services group and will mark the introduction of
GeneNews' BreastSentry® diagnostic test to the U.S. market.
Patients of this medical group, which prefers not to have its
name published, will now have access to GeneNews' innovative
screening tests – ColonSentry®, earlyCDT®-Lung, Prostate Health
Index, and the new BreastSentry® diagnostic test – which provide
early risk stratification of colorectal cancer, lung cancer,
prostate cancer and breast cancer, respectively. All four
screenings utilize a quick and convenient blood test that can be
completed through designated medical clinics.
GeneNews will process the samples through its CAP and
CLIA-certified Innovative Diagnostic Laboratory ("IDL") clinical
reference laboratory in Richmond,
Virginia, and provide individualized risk stratification
reports for each patient, the supply of testing kits and ongoing
consultation. JTS Health Partners, based in Atlanta, Georgia, will work with both GeneNews
and the medical group within the planning and implementation
phase.
"We are pleased to partner with this leading physician group,
which will be the first to offer our BreastSentry® diagnostic, a
blood test that predicts a patient's risk of developing breast
cancer in the ensuing five years, as well as estimating life time
risk," commented James R Howard-Tripp. "As with most cancers, the
early identification of high risk patients is critical to improved
decision making and treatment. We are confident that this test will
be well-received by patients and look forward to making it more
widely available throughout the United
States in the coming months.
About GeneNews
GeneNews is committed to becoming a leader in advanced
diagnostics and personalized medicine, serving as a strong
commercialization outlet for early detection of cancer and other
chronic diseases. Our mission is to identify, assess and make
commercially available a comprehensive menu of diagnostics that
provide physicians and patients with personalized clinical
intelligence and actionable information to improve health out-comes
through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic
Laboratory clinical reference lab specializes in traditional and
advanced clinical evidence-based blood testing that helps find,
understand, and address cancer risk in patient populations.
Currently, IDL offers risk assessment blood tests for the four most
prevalent cancer types - colon, lung and prostate. GeneNews' common
shares trade on the Toronto Stock Exchange under the symbol
'GEN'. More information on GeneNews can be found at
www.GeneNews.com.
About JTS Health Partners
The Company is partnered with JTS Health Partners of
Atlanta, Georgia. Their healthcare
management consulting and services portfolio is focused on
enterprise advisory planning, health information management,
information technology, financial and revenue cycle management.
More information on JTS can be found at
www.jtshealthpartners.com.
Forward-Looking Statements
This press release contains forward-looking statements
identified by words such as "expects", "will" and similar
expressions, which reflect the Company's current expectations
regarding future events. The forward-looking statements involve
risks and uncertainties that could cause the Company's actual
events to differ materially from those projected herein. Investors
should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties
relating to these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. The
Company disclaims any obligation to update these forward-looking
statements, except as required by law.
SOURCE GeneNews Limited